Neil Bander

[Thomas Hope @thomashopemd]

And then there were three. @TelixPharma gets approval for their 68Ga-PSMA-11 kit (called ILLUCCIX). Same clinical data as in the UCSF/UCLA prescribing information. Great to see that data lead to an approval of the agent that will be available more widely!

[Neil Bander @nhbander]

@EricKleinMD could he have been an outfielder 😊

[Neil Bander @nhbander]

@EricKleinMD @CleClinicUro @CleClinicNeph @Stanford Bravo Eric, job incredibly well done. Enjoy your new adventure.

[Neil Bander @nhbander]

@DrMHofman @ChrisSweens1 @piet_ost @ANZUPtrials @Uromigos @Silke_Gillessen @declangmurphy @lawrentschuk @gu_onc @SNM_MI IMO not literally accurate to say that PSMA PET images tumor activity; it images PSMA expression which reflects tumor/AR activity. In this example, where PSA and PSMA have become undetectable, suggests AR activity has been eliminated. BUT, there could be viable small cell/NE tumr

[Jeff Bulte @BulteJeff]

RIP Sanjiv Sam Gambhir, 1962-2020. A founding father of Molecular Imaging and one of my role models. Hard to believe what a family can go through.

[Neil Bander @nhbander]

actually 41% PSA50 with 2/3 of those being PSA75. Not bad considering no PSMA selection, only single dose, and as you say, majority with prior LuPSMA. 6 with grade 1 xerostomia, 5 of whom had prior LuPSMA. Mutli-dose to start soon.

[GU Cast | Urology podcast! @gu_onc]

Thanks @piet_ost! A great team working on these prospective LU-PSMA studies @DrMHofman @AzadOncology @declangmurphy @PeterMacCC @PeterMacRes @ANZUPtrials @MovemberAUS @PCF_Science @soulehoward1

[Neil Bander @nhbander]

@PCF_Science #Prostatejc WCM has clinical data in an ongoing randomized multicenter trial of hi-risk M0 patients Rx with J591-Lu177 that is informative and impressive. Look forward to finishing [+/- 8 slots left] and releasing data.

[Neil Bander @nhbander]

@PCF_Science #Prostatejc Heterogeneity is a fact of life with all cancers esp PC. It’s true of AR, PSMA, etc. PSMA is no more heterogen than AR; in fact the 2 are inextricably linked. Is heterogen so significant to abrogate clinical benefit? I think NOT.

[Neil Bander @nhbander]

@PCF_Science #Prostatejc Combining anti-AR + PSMA targeting is synergistic. Anti-AR increases PSMA and decreases DDR. Trick will be treating patients before they are end stage.

[Neil Bander @nhbander]

WCM has clinical data in an ongoing randomized multicenter trial of hi-risk M0 patients Rx with J591-Lu177 that is informative and impressive. Look forward to finishing [+/- 8 slots left] and releasing data.

[Neil Bander @nhbander]

Heterogeneity is a fact of life with all cancers esp PC. It’s true of AR, PSMA, etc. PSMA is no more heterogen than AR; in fact the 2 are inextricably linked. Is heterogen so significant to abrogate clinical benefit? I think NOT.

[Neil Bander @nhbander]

Combining anti-AR + PSMA targeting is synergistic. Anti-AR increases PSMA and decreases DDR. Trick will be treating patients before they are end stage.

[Neil Bander @nhbander]

definitely true.

[Neil Bander @nhbander]

@PCF_Science @EUplatinum @jodebon @boragurel @ICR_London @soulehoward1 @LoebStacy @BanderNeil @DrScottTagawa @michael_gorin @pienta_brady @PCFnews My prediction is that with a multi-variate analysis of PSMA & DDR that includes AR, the PSMA/DDR relationship will drop out. Johann I believe feels otherwise. Maybe his, or another group, can do the analysis and let us know the answer? #ProstateJC

[Neil Bander @nhbander]

#prostatejc we did use folate-free media + supplemented with step-wise addition of folate from 0 to pharmacologic levels. In concert, we measured PSMA expression levels hoping to see rising PSMA in response to lowered folate. We saw flat PSMA across [folate]. Do you see otherwise

[Neil Bander @nhbander]

@jodebon #ProstateJC i agree. By hammering patients with potent ARis, we're driving them to an AR- state with an abysmal prognosis. PeterMac group has reported ultrashort survival in those pts who did not qualify for PSMA Rx.

[Neil Bander @nhbander]

#ProstateJC Can you quantify 'many'. I suspect these are the PSMA-/FDG+ cases described by Hofman et al. My recollection is this was around 17% in their series. Liver mets post abi/enz=>likely small cell/NET--AR-/PSMA-. Not surprising to me.

[Neil Bander @nhbander]

I suspect you're seeing a population skewed toward abi/enza failures; that may contribute to 'many'. Not surprising given the widespread use of abi/enz. Not likely good candidates for PSMA targeting.